Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00929565|
Recruitment Status : Completed
First Posted : June 29, 2009
Last Update Posted : April 9, 2012
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.
The investigators plan to measure these factors prior to and after bronchoscopy.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Observational Model:||Case Control|
|Official Title:||Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||October 2011|
Comparison between individuals with and without pulmonary malignancy
- Volume of blood loss during the procedure [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00929565
|United States, Oklahoma|
|VA Medical Center|
|Oklahoma City, Oklahoma, United States, 73104|
|Principal Investigator:||Jijo John, MD||University of Oklahoma|